Rational use of mucoactive medications to treat pediatric airway disease

Many airway diseases in children, notably bronchiolitis, cystic fibrosis (CF), non-CF bronchiectasis including primary ciliary dyskinesia, pneumonia, and severe asthma are associated with retention of airway secretions. Medications to improve secretions clearance, the mucoactive medications, are emp...

Full description

Saved in:
Bibliographic Details
Published in:Paediatric respiratory reviews 2020-11, Vol.36, p.8-14
Main Authors: Linssen, R.S.N., Ma, J., Bem, R.A., Rubin, B.K.
Format: Article
Language:English
Subjects:
Adolescent
Adrenal Cortex Hormones - therapeutic use
Airway diseases
Asthma - drug therapy
Bronchiectasis - drug therapy
Bronchiolitis, Viral - drug therapy
Child
Child, Preschool
Cholinergic Antagonists - therapeutic use
Ciliary Motility Disorders - drug therapy
Cystic fibrosis
Cystic Fibrosis - drug therapy
Deoxyribonuclease I - therapeutic use
Diuretics, Osmotic - therapeutic use
Dornase
Epithelial Sodium Channel Blockers - therapeutic use
Expectorants - therapeutic use
Humans
Infant
Macrolides - therapeutic use
Mannitol
Mini-symposium: Diagnosis and management of pulmonary lymphatic disorders
Mucoactive medications
Mucolytics
Recombinant Proteins - therapeutic use
Respiratory System Agents - therapeutic use
Saline Solution, Hypertonic
Severity of Illness Index
Sputum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many airway diseases in children, notably bronchiolitis, cystic fibrosis (CF), non-CF bronchiectasis including primary ciliary dyskinesia, pneumonia, and severe asthma are associated with retention of airway secretions. Medications to improve secretions clearance, the mucoactive medications, are employed to treat these diseases with varying degrees of success. This manuscript reviews evidence for the use of these medications and future directions of study.
ISSN:1526-0542
1526-0550
1526-0550
DOI:10.1016/j.prrv.2020.06.007